REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2021.01.11 | 22:30 | Permanent Information Releases / General Company News

puce Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene - HTML (w)

2020.12.18 | 22:50 | Permanent Information Releases / General Company News

puce Novartis receives complete response letter from U.S. FDA for inclisiran - HTML (w)

2020.12.16 | 01:17 | Permanent Information Releases / General Company News

puce Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF - HTML (w)

2020.12.15 | 07:15 | Permanent Information Releases / Sales and Revenues

puce Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema - HTML (w)

2020.12.14 | 07:15 | Permanent Information Releases / General Company News

puce Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 - HTML (w)

2020.12.09 | 15:45 | Permanent Information Releases / General Company News

puce Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer - HTML (w)

2020.12.09 | 15:00 | Permanent Information Releases / General Company News

puce Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer - HTML (w)

2020.12.08 | 16:00 | Permanent Information Releases / General Company News

puce Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial - HTML (w)

2020.12.05 | 16:00 | Permanent Information Releases / General Company News

puce Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas - HTML (w)

2020.12.04 | 18:30 | Permanent Information Releases / General Company News

puce Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD - HTML (w)

2020.11.24 | 07:00 | Permanent Information Releases / General Company News

puce Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event - HTML (w)

2020.11.19 | 22:30 | Permanent Information Releases / General Company News

puce Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy - HTML (w)

2020.11.19 | 15:43 | Permanent Information Releases / General Company News

puce New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases - HTML (w)

2020.11.19 | 07:15 | Permanent Information Releases / General Company News

puce Novartis set to achieve 100% renewable electricity in its European operations - HTML (w)

2020.11.13 | 16:00 | Permanent Information Releases / General Company News

puce New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1384